Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

Table 1: Kinase Activity and Ligand Binding Capability ... What steps did scientists take to learn the basics about ERBB activation? EGFR has been the most extensively studied with respect to ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

Improve workflow and productivity — when patients arrive for imaging sessions without a current creatinine/eGFR workup, the StatSensor Creatinine POC testing can avoid workflow interruptions and ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.